Related Experiment Video
Updated: Jan 7, 2026

Transcranial Direct Current Stimulation tDCS for Memory Enhancement
Published on: September 18, 2021
Dementia Care Research and Psychosocial Factors
Hannah Brown1, Simone Gabriele1, Georgia Giannakopoulou1
1Ipsos, London, London, United Kingdom.
Background:
Blood-based biomarker tests for Alzheimer's Disease (AD) are showing promise in clinical trials and are expected to improve the accuracy of diagnosis. By facilitating earlier detection, these tests could enable more individuals to qualify for recently approved disease-modifying therapies (DMTs). This study assessed public willingness to undergo such blood tests.
Method:
An online survey was conducted in August 2024 with 804 adults aged 18 years or older from the US (n = 106), EU4+UK (France, Germany, Italy, Spain, UK; n = 517), Japan (n = 106), and China (n = 75). Respondents were screened to ensure some understanding of, but not currently diagnosed with, AD. Participants were presented with a hypothetical scenario in which they were experiencing symptoms of mild cognitive impairment (MCI). They rated their willingness to take a blood test to confirm whether these symptoms were due to AD on a 7-point scale (1 = Not at all willing, 7 = Very willing). Ratings of 6 or 7 were considered "very willing" (Top 2 Box, T2B).
Results:
Overall, 53% of respondents indicated high willingness (T2B) to take the blood test. Willingness was highest in the US (66%) and lowest in Japan (27%) (p < 0.05). Lower willingness reported in Japan may be influenced by a cultural tendency to avoid extreme responses in surveys. Significant factors associated with higher willingness included better understanding of the disease, personal experience with AD, greater concern about developing AD, and closer proximity to support networks. A significant association was also observed between willingness to undergo a blood test and subsequent willingness to take treatment if MCI were confirmed but symptoms were not yet impacting day-to-day life. Among the 427 individuals willing to take a test, 77% were very willing (T2B) to take treatment, compared to 39% among the 125 individuals not willing to take a test.
Conclusions:
In this study cohort, variations exist in willingness to undergo blood testing for AD confirmation among different subgroups. These findings suggest that personal experience and knowledge of AD play crucial roles in shaping attitudes toward diagnosis. Consequently, educational initiatives may need to be differentiated for certain subgroups.
More Related Videos
08:36The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
Published on: July 28, 2022
10:13Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
Published on: February 14, 2014
Related Concept Videos
Dementia
The progression of dementia is generally gradual....
Psychological and Sociocultural Causes of Schizophrenia
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Cognitive Development During Adulthood
Documentation in Long-Term and Home Healthcare Setting
Long-Term Care Facilities